Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
14 EllsworthM
21st ed
First, most data evaluating combined SGLT2 inhibitor and GLP-1 receptor agonist therapy derive from post hoc analyses, subgroup analyses, observational cohorts, or trials primarily designed for glycemic or cardiovascular outcomes rather than dedicated heart failure endpoints
British J Clin Pharmacol
doi: 10.1016/j.ccell.2016.10.005 117 FurneySJPedersenMGentienDDumontAGRapinatADesjardinsLet al
The survey included questions regarding drug brand, dosing regimen, time on treatment, efficacy (including pre-treatment weight and weight on treatment), and side effects, as well as reasons for pursuing or stopping GLP1 treatment
US$ 21.12
US$ 23.81
US$ 22.41
